Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Objective—Glucagon-like peptide ... 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell ...

Multivitamins are also recommended as it ensures you are not running low on any essential vitamins and minerals. Because ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Semaglutide (Wegovy and Ozempic): Originally developed for type 2 diabetes, this medication mimics the GLP-1 hormone, ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Naturally, they had to then investigate their functions more closely ... These drugs mimic the effects of the GLP-1 hormone, which is naturally released from the gut after eating.

FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage FDAs latest insulin biosimilar approval aims to mitigate ongoing supply challenges in the U.S.

In recent months, the efficacy of contraception for people taking weight loss medications has been questioned, as several women claim to have gotten pregnant despite using oral contraceptives.

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...